title: Kaposi's sarcoma and other manifestations of human herpesvirus 8.
abstract: Kaposi's sarcoma (KS) was described by Moritz Kaposi in 1872 and was known for an entire century as a rare disorder of older men usually of Eastern European, Mediterranean, and/or Jewish origin. In the early 1980s, the prevalence of KS began to increase dramatically and soon became the most common malignancy in patients with AIDS, especially those who were male homosexuals. In 1994, a new human herpesvirus (HHV) was found to be present in almost 100% of KS lesions. This virus was found to be a gammaherpesvirus, closely related to Epstein-Barr virus, and was designated HHV-8. Subsequently, HHV-8 DNA was found in almost all specimens of classic KS, endemic KS, and iatrogenic KS, as well as epidemic KS (ie, AIDS KS). It is now believed that HHV-8 is necessary, but not sufficient, to cause KS and that other factors such as immunosuppression play a major role. The use of highly active antiretroviral therapy (HAART) since 1996 has markedly reduced the prevalence of AIDS KS in western countries, but because 99% of the 40 million patients with AIDS in the world cannot afford HAART, KS is still a very common problem. Primary effusion lymphoma and multicentric Castleman's disease are also thought to be due to HHV-8. Although HHV-8 DNA has been described in a number of other cutaneous disorders, there is little evidence that HHV-8 is of etiologic significance in these diseases. The mechanism by which HHV-8 causes KS, primary effusion lymphoma, and multicentric Castleman's disease is not well understood but is thought to involve a number of molecular events, the study of which should further our understanding of viral oncology. (J Am Acad Dermatol 2002;47:641-55.)
  
  
  OBJECTIVE
  At the completion of this learning activity, participants should be familiar with Kaposi's sarcoma and other manifestations of human herpesvirus 8.
authors.affiliation: Department of Dermatology, University of Illinois at Chicago, IL, USA.
authors.forename: Pedram
authors.initials: P
authors.lastname: Geraminejad
authors.forename: Omeed
authors.initials: O
authors.lastname: Memar
authors.forename: Iris
authors.initials: I
authors.lastname: Aronson
authors.forename: Peter L
authors.initials: PL
authors.lastname: Rady
authors.forename: Ulrich
authors.initials: U
authors.lastname: Hengge
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Tyring
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D005871:Castleman Disease / Q000821:virology; D015696:Gene Products, tat / Q000235:genetics; D006566:Herpesviridae Infections / Q000821:virology; D019288:Herpesvirus 8, Human / Q000502:physiology; D006801:Humans; D015850:Interleukin-6; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000821:virology; D016366:Open Reading Frames / Q000502:physiology; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D016036:Seroepidemiologic Studies
chemical_list: D015696:Gene Products, tat; D015850:Interleukin-6